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Challenges of drug resistance in the developing world
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more difficult problem in poorer countries
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Resistance to anti-infective drugs, particularly bacterial
resistance to antibiotics, is a global phenomenon. Resistant
infections increase morbidity and mortality and prolong the
time of infectiousness, putting others at risk. In high income
countries, where the burden of infectious diseases is modest,
the decreasing effectiveness of first line antibiotics is overcome
by more expensive second and third line antibiotics. The
challenge is greater in developing countries, where the burden
of infectious diseases is high and patients with a resistant
infection may be unable to obtain or afford any antibiotic, let
alone expensive second line treatments. Poor hygiene, unreliable
water supplies, civil conflicts, and increasing numbers of
immunocompromised people with HIV infection, facilitate both
the evolution of resistant pathogens and their rapid spread.1 2
The most complete data on resistance in developing countries
come from tertiary care facilities, typically located in large
cities. Very little information exists on resistance in other
settings and almost none in rural areas. Recent data from
community settings in Indian and South African urban and
peri-urban areas indicate that levels of resistance are high. In
urine specimens collected from November 2003 to December
2004, more than 70% of Escherichia coli isolated from healthy
women were resistant to ampicillin and nalidixic acid, and more
than 50% of isolates were resistant to fluoroquinolones (fig 1⇓).
3
Causes of resistance
Increasing use of antibiotics
Bacterial selection for antibiotic resistance is a natural
phenomenon related to the volume of antibiotics used: the more
these drugs are used the quicker resistant strains emerge and
spread.4 This is true whether antibiotics are medically indicated
or not. Antibiotic use is increasing, particularly in Asian and
Latin American countries where rising incomes are enabling
greater access. The delicate balance in developing countries is
between encouraging greater use for appropriate
indications—consider the one million deaths of children each
year from pneumonia, much of it untreated—and the
overwhelming tendency for inappropriate use of antibiotics for
coughs, colds, and diarrhoea. In India, per capita antibiotic use
increased by 37% between 2005 and 2010, and the fastest
growth was in broad spectrum penicillins, cefalosporins,
previously unaffordable quinolones, and carbapenems.5 In low
and middle income countries with a high HIV burden, the use
of cotrimoxazole to treat opportunistic infections has increased
resistance in pneumococci and E coli.6
There is little incentive for patients or healthcare providers to
consider the effect of their decisions to use antibiotics on overall
levels of resistance. Some health workers, for example, increase
their incomes by selling antibiotics to their patients. In Central
China, doctors profit from prescribing and treating insured
patients with more expensive antibiotics.7 Prescribing behaviour
in every country is also influenced by medical training and
culture and social norms and expectations related to the need
for and use of antibiotics.8
Institutional incentives may have a role in higher than necessary
antibiotic prescribing. In China, many hospitals rely on drug
sales for income; one study estimated that a quarter of revenue
in two hospitals was derived from antibiotic sales.9 In India,
doctors routinely receive compensation from drug sellers in
exchange for directing patients to their pharmacies. Insured
patients are more likely to be prescribed antibiotics than those
without insurance, as they are less affected by cost.10
Competition from unsanctioned providers also exacerbates
competitive pressure on legitimate medical professionals.
Up to 90% of antibiotic use in certain developing countries is
over the counter, without a prescription, and non-prescription
sales are common in nearly every such country.11 Despite
concern that use of antibiotics without a prescription contributes
to resistance, there is little evidence that physicians prescribe
antibiotics more appropriately than do trained pharmacists or
untrained pharmacy attendants—they all overprescribe, though
trained providers may do somewhat better. One reason may be
that pharmacists and shopkeepers often mimic prescribing
patterns of local healthcare providers and copy both desirable
and undesirable practices. A study from Thailand found that a
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pharmacy’s proximity to a hospital improved the appropriateness
of antibiotics sold.12
Diagnostic tests for infections are commonly unavailable or
unreliable in developing countries.13 In Malaysia, even in
hospitals with diagnostic facilities, tests were used in only 20%
of cases where it was thought that antimicrobials were
indicated.14 In many countries, diagnostics are still relatively
expensive and must be paid for directly by the patient: it is
cheaper to use an antibiotic first. Easy to use and inexpensive
point-of-care diagnostics could resolve some of these problems,
but their development remains a challenge, for technical and
economic reasons.
Missed opportunities
Antibiotic use is also driven by missed opportunities to reduce
the overall burden of infections. Drug resistance in healthcare
settings may be exacerbated by poor infection control and
overcrowding of hospitals, particularly public hospitals. A recent
point prevalence study of 1265 intensive care units in 75
countries found that 51% of intensive care patients were
considered to have an infection and 71% were receiving
antimicrobial drugs, some for prophylaxis (somewhat higher
than reported in a similar survey in 17 countries in western
Europe 15); most patients were receiving two or more
antibiotics.16Most hospital acquired infections in low andmiddle
income countries are, as in high income countries, caused by
difficult to treat Gram negative organisms.
Low immunisation rates contribute to a high burden of disease
that is potentially avertable. In India, less than half of all children
are fully immunised with the routine vaccines.17 Use of the
pneumococcal conjugate vaccine (PCV) has lowered infection
rates and therefore antibiotic use and resistance in the United
States18 19 but has been adopted in very few low and middle
income countries. The association of HIV infection with child
serotypes of pneumococci and antibiotic resistance suggests
that vaccination could reduce the burden of pneumococcal
resistance, making it potentially even more valuable in
developing countries.20 21
Other causes
Finally, non-human, environmental use of antibiotics is thought
to be contributing to selection pressure on resistant strains. In
China and Vietnam, demand for meat is driving use of
antibiotics to promote growth in poultry and pigs and to keep
disease in check where animals are crowded together.22 23
Environmental contamination with antibiotics or their residues
by drug manufacturers in low income countries is a growing
problem. Up to 45 kg of ciprofloxacin a day— the equivalent
of 45 000 daily doses—wasmeasured in a river close to factories
producing this antibiotic.24 Scientific evidence linking
environmental antibiotic selection pressure and resistance in
humans remains elusive, but geographical similarities in
resistance patterns of human zoonotic and animal infections
give reasons to suspect cause and effect.
Consequences of resistance
Despite numerous studies indicating that antibiotic resistance
is increasing, little has been done to quantify the attributable
burden of resistance in developing countries. The EPIC II study
found that infection with multidrug resistant staphylococci,
Acinetobacter and Pseudomonas species, and fungal pathogens
was statistically correlated with excess mortality.16A study from
Thailand found mortality as high as 67% for meticillin resistant
Staphylococcus aureus and 46% for meticillin susceptible S
aureus, significantly higher than in high income countries.25
However, a causal relation between resistance and mortality is
difficult to prove because the risk factors for infection with a
resistant pathogen, including length of stay in intensive care,
are similar to those causing worse outcomes in patients without
resistant pathogens. Community based studies have linked
chloroquine resistance to increased mortality from malaria,26
and similar studies are needed to understand the consequences
of drug resistance in pneumococci, E coli, and staphylococci in
developing countries.
Resistance is likely to result in the need for more expensive
second line antibiotics, which may be less readily available in
developing countries. A recent survey found that the retail price
of generic ciprofloxacin, often used as a second line antibiotic,
is higher in low and middle income countries than in high
income countries, indicating that the economic burden of
resistance to first line drugs may be greater in poorer countries
(fig 2⇓).
The way forward
We need to increase awareness among national policy makers
in both industrialised and developing countries about controlling
antibiotic resistance. The policy goals should be to selectively
reduce inappropriate use of antibiotics, increase appropriate use
to treat and prevent disease, and reduce the need for
antibiotics—a challenge in the context of weak public health
systems and private systems that benefit from drug sales.28 Easy
over-the-counter access to antibiotics is a further problem, and
it is often difficult to balance improved access to drugs with
resistance concerns. A fundamental challenge is that patients,
physicians, hospitals, and drug companies have little incentive
to consider resistance related costs when deciding how to use,
prescribe, or sell antibiotics. But developing countries do not
have the luxury of allowing increases in use without taking steps
to manage resistance. Reducing the burden of infections through
immunisations and hospital infection control could greatly
reduce the reliance on antibiotics. Despite strong evidence of
benefits, progress on Haemophilus influenzae type B and
pneumococcal vaccinations has been slow because of economic
and other constraints, and no vaccines exist for many other
common infections.
Countries could readily adopt steps to accomplish some of these
ends while others require long term investment by a range of
global players. At present, most evidence of effectiveness for
specific interventions comes from high income settings. A
challenge, increasingly being taken up, is in adapting
interventions to conditions in developing countries, but greater
efforts are needed.
Antimicrobial resistance competes with other pressing public
health challenges for policy makers’ attention. Without sound
evidence on the attributable mortality of resistant infections at
a national level, it may be difficult to draw resources to this
problem, which is urgent but not as obvious as HIV/AIDS or
an epidemic of dengue fever, for instance. Similarly, evidence
is needed to promote creative solutions that recognise limited
regulatory capacities in many low andmiddle income countries.
For instance, a ban on non-prescription sales of antibiotics is
likely to be both unenforceable and counterproductive because
it may restrict access for poorer populations that rely on private
drug sellers for health care. Efforts like the AffordableMedicine
Facilities-malaria (AMFm) are promoting the use of
coformulations of antimalarials that are less likely to lead to
resistance and providing high quality drugs at an affordable
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price. Similar initiatives could be developed for antibiotics, but
they must be accompanied by monitoring for resistance.
Ultimately, the way forward will be a combination of many
different interventions—better infection control, more
appropriate use of antibiotics; research and development of new
antibiotics, vaccines, and inexpensive point-of-care diagnostics;
less environmental contamination with antibiotics; and stronger
surveillance and containment of resistant strains.
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Figures
Fig 1 Antibiotic resistance in E coli isolated in New Delhi during 2003-4
Fig 2 Cost of course of generic ciprofloxacin (500 mg) in selected countries, 30 November 200927
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